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Targeted anion transporter delivery by coiled-coil
driven membrane fusion†
Nestor Lopez Mora,a Azadeh Bahreman,a Hennie Valkenier,‡b Hongyu Li,c
Thomas H. Sharp,d David N. Sheppard,c Anthony P. Davis*b and Alexander Kros*a
Synthetic anion transporters (anionophores) have potential as biomedical research tools and therapeutics.
However, the eﬃcient and speciﬁc delivery of these highly lipophilic molecules to a target cell membrane is
non-trivial. Here, we investigate the delivery of a powerful anionophore to artiﬁcial and cell membranes
using a coiled-coil-based delivery system inspired by SNARE membrane fusion proteins. Incorporation of
complementary lipopeptides into the lipid membranes of liposomes and cell-sized giant unilamellar
vesicles (GUVs) facilitated the delivery of a powerful anionophore into GUVs, where its anion transport
activity was monitored in real time by ﬂuorescence microscopy. Similar results were achieved using live
cells engineered to express a halide-sensitive ﬂuorophore. We conclude that coiled-coil driven
membrane fusion is a highly eﬃcient system to deliver anionophores to target cell membranes.
Introduction
There is urgent interest in Drug Delivery Systems (DDSs), such
as cell penetrating peptides or liposomes, which are non-inva-
sive and cause no damage to cellular membranes.1 Liposomes
of less than 1 mm in diameter have been used as models for
studying biological and biophysical membrane properties, as
well as DDSs, due to their biocompatibility and low toxicity.
Delivery of molecules into the cytoplasm of cells can be ach-
ieved by functionalizing liposomes with positively charged
lipids, polymers, antibodies or cell penetrating peptides.2,3
Whilst the encapsulation of water-soluble drugs into liposomes
is one of themost used tools for drug delivery, the incorporation
of lipophilic drugs into the phospholipid bilayer of liposomes
has been less exploited.4,5 Alternative approaches to delivering
drugs with low water-solubility include the use of solubilizing
agents or vehicles, such as micelle forming amphiphiles,6
cyclodextrins7 or cucurbiturils,8 although these are not targeted
and tend to have limited stability.
One class of lipophilic compounds that could benet from
novel DDSs are transmembrane anion transporters (aniono-
phores).9 These molecules have potential as tools for biomed-
ical research, and might also replace the function of anion
channels which are defective or decient in genetic
diseases.10–13 There is particular interest in bypassing the cystic
brosis transmembrane conductance regulator (CFTR) whose
dysfunction causes cystic brosis.14–16 Anionophores require
suﬃcient lipophilicity to partition exclusively into the
membrane and to carry anions such as chloride across the
apolar membrane interior.17 They therefore tend to be water-
insoluble, with low intrinsic deliverabilities using conventional
DDS.18,19
Inspired by the specic molecular recognition of native
SNARE proteins,20,21 we have developed a DDS employing
a synthetic model system to induce targeted membrane
fusion.22,23 Our membrane fusion system consists of the use of
two complementary peptide amphiphiles located in diﬀerent
membranes.24 The formation of a dimeric coiled-coil by these
peptides brings the two opposing membranes into close prox-
imity, thereby inducing eﬃcient membrane fusion.25 In
previous work, we successfully used this coiled-coil motif to
modify surfaces of cancer cells and one-day-old zebra sh
embryos in vivo.26,27
Herein, we report the use of this DDS as a highly specic
recognition system for delivering a lipophilic anion transporter
to both giant unilamellar vesicles (GUVs) and the plasma
membrane of cells. The pair of complementary lipopeptides
employed in this study is presented in Scheme 1. This synthetic
model system is constructed from two complementary amphi-
philic coiled-coil peptides K4 [(KIAALKE)4] (1) and E4
[(EIAALEK)4] (2) coupled to a cholesterol anchor through
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a exible polyethylene glycol linker. The heterodimeric coiled
coil acts as a molecular zipper by the binding of two a-helical
peptide strands, while the cholesterol anchor allows the inser-
tion of the peptides into the lipid membrane of vesicles or cells.
The anionophore bis-(thioureido)decalin (3) has remarkable
ability to transport anions across lipid bilayers, promoting rapid
chloride–nitrate exchange even when operating as single
molecules.28 Recently, we evaluated the activity of 3 in
individual GUVs by its direct incorporation into the lipid
mixture prior to GUV formation. The average initial rate of
chloride transport per molecule was determined by analyzing
the quenching of the halide-sensitive uorophore lucigenin
encapsulated in the GUVs.29 Transporter 3 showed exceptional
chloride/nitrate exchange activity (820  260 Cl/s) when
incorporated a priori into the lipid membrane of liposomes or
GUVs at diﬀerent concentrations. However, the high lip-
ophilicity of 3 limits its deliverability. Not only is it poorly
delivered when added in methanol, but the use of simple vesi-
cles as delivery vehicles is also ineﬀective (Fig. S1 in the ESI†).
The poor deliverability of 3 and similar anionophores is
a critical barrier to future applications. When rates of anion
transport were studied in cells, the best performance was ob-
tained by an anionophore with excellent deliverability, but
modest intrinsic activity (two orders of magnitude lower than 3
in liposomes).19 Thus, solving the deliverability problem of 3
has great potential for applications in biophysics and perhaps
therapeutics. Here we present a facile method to deliver the
highly lipophilic transporter 3 pre-incorporated in liposomes by
simple incubation with GUVs and cells.
Fig. 1 outlines the protocol for delivering transporter 3 to the
lipid membrane of cell-sized GUVs using our synthetic
membrane fusion system. The experimental design comprises
three main components: (i) GUVs functionalized with
Scheme 1 Chemical structures of the synthetic membrane fusion
model: lipopeptide CP4K4 (1), lipopeptide CP4E4 (2) and the aniono-
phore bis-(thioureido)decalin (3).
Fig. 1 Schematic of the targeted delivery of lipophilic transporter 3 by membrane fusion. GUVs (70% POPC and 30% cholesterol) encapsulating
0.8 mM lucigenin ﬂuorophore are incubated with lipopeptide 1 to functionalize the lipid membrane of the GUV. Subsequent formation of
a dimeric coiled-coil allows the fusion of liposomes containing 10mol% transporter 3 and the complementary lipopeptide 2, resulting in targeted
delivery of 3 to the membrane of the GUV. Finally, upon the addition of NaCl to the exterior solution, transporter 3 exchanges external chloride
for internal nitrate, resulting in the quenching of the encapsulated lucigenin ﬂuorophore.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 1768–1772 | 1769
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lipopeptide 1 as the target membrane and biophysical cell
model; (ii) the halide sensitive uorophore lucigenin encapsu-
lated in the GUVs as a sensing dye and (iii) the DDS which uses
liposomes decorated with lipopeptide 2, and with transporter 3
incorporated a priori into the lipid membrane. Following tar-
geting and incorporation of anionophore 3 into the lipid
membrane of GUVs by membrane fusion, the quenching of
lucigenin uorescence by chloride is used to measure the
chloride transport activity.
Results and discussion
Liposomes were formed from the lipid mixture 1-palmitoyl-2-
oleoylphosphatidylcholine (POPC) and cholesterol in a 7 : 3
molar ratio by sonication method in the presence of 10 mol%
transporter 3 and 1 mol% lipopeptide CP4E4 (see ESI for
experimental details†). The hybrid lipid lm was hydrated in an
aqueous solution of 225 mM NaNO3, 10 mM Tris and 200 mM
glucose (pH ¼ 7, adjusted with H2SO4) and sonicated for 4
minutes at 50–55 C. Liposome formation was conrmed by
dynamic light scattering measurements (Fig. S2 and S3 in the
ESI†) and the peptide functionalized liposomes were charac-
terized by cryo-transmission electron microscopy (cryoTEM) in
the absence and presence of transporter (Fig. S4 in the ESI†).
Electron microscopy showed that the lipid membrane of the
CP4E4 functionalized liposomes was not altered by the incor-
poration of 3.
In parallel, GUVs were grown by lipid lm hydration (POPC
and cholesterol, 7 : 3 molar ratio) on chemically crosslinked
dextran (polyethylene glycol) hydrogel (DexPEG) substrates.30
The hydration of the lipid lm was performed with a solution of
225 mM NaNO3, 10 mM Tris, 200 mM sucrose and 0.8 mM
lucigenin at room temperature. The DexPEG hydrogel allows
both the eﬃcient encapsulation of the lucigenin uorophore
and the growth of GUVs under the high ionic strength condi-
tions which are required to perform chloride/nitrate exchange.
Lucigenin-loaded GUVs were subsequently functionalized
with CP4K4 by incubation in a solution containing lipopeptide
1. Even though it is possible to grow GUVs with lipopeptide 1
pre-incorporated directly into the lipid mixture, we chose to
make plain GUVs and modify them a posteriori with lipopeptide
1 because our aim is to deliver the transporter to cellular
membranes, which do not contain 1 as a specic recognition
motif. As mentioned above, we showed previously that similar
cholesterol modied lipopeptides can be inserted eﬃciently
into liposomal membranes31 and the plasma membrane of
cancer cells26 by simple incubation. In the present work, we
followed the same procedure for the peptide functionalization
of GUVs. Briey, aer the formation of lucigenin loaded GUVs,
300 mL of the solution containing the GUVs was transferred to
700 mL of solution containing 225 mM NaNO3, 10 mM Tris, 200
mM glucose and 1 mM CP4K4 (1). GUVs were incubated for one
hour at room temperature to allow the incorporation of mole-
cule 1 into the membrane of GUVs. The higher density of the
sucrose lucigenin solution encapsulated in GUVs compared to
external glucose solution caused the GUVs to sink to the bottom
of the micro centrifuge tube. Transfer of sedimented GUVs to
fresh external solution in further steps also enabled the removal
of the excess of non-encapsulated lucigenin uorophore.
Liposome–GUV membrane fusion was initiated by treating
peptide 1-functionalized GUVs (20 mm diameter) containing
the chloride-sensitive lucigenin uorophore with peptide 2-
decorated liposomes (150 nm diameter) containing 3 pre-
incorporated in the lipid membrane (Fig. 1). Briey, CP4K4
membrane-functionalized GUVs (200 mL) and CP4E4 membrane-
functionalized liposomes (100 mL) were combined in 700 mL of
225mMNaNO3, 10mMTris and 200mM glucose solution. Aer
gentle mixing for 15 minutes using a rotary shaker, the mixture
was incubated for 105 minutes more at room temperature to
allow fusion of liposomes with GUVs and concomitant delivery
of transporter 3 to the lipid bilayer of GUVs. Finally, 200 mL of
the sedimented sucrose-containing GUVs were taken from the
bottom of the micro centrifuge tube and transferred to
a chamber on the stage of a confocal microscope with 100 mL of
225 mM NaNO3, 10 mM Tris and 200 mM glucose. The integrity
of GUVs following membrane fusion was veried by confocal
uorescence (excitation at 488 nm) and bright eld imaging.
To test for delivery of transporter 3 to the GUV membranes,
the chloride-permeability of the GUVs was assayed through
lucigenin uorescence. NaCl (25 mL, 1 M solution) was added
with a microsyringe to the microscope chamber containing the
GUVs, and the lucigenin emission intensity was observed to
decay markedly over a period of 3 minutes (Fig. 2, blue
triangles). The quenching of lucigenin uorescence aer
delivery of transporter 3 (76% aer 3 minutes) was signicantly
stronger than the eﬀect of photobleaching (9% aer 3 minutes;
Fig. 2, black squares). This result agrees well with previous
experiments where transporter 3 was pre-incorporated into the
lipid bilayer of GUVs for direct visualization of chloride trans-
port into GUVs.29 Thus, membrane fusion eﬃciently delivered
transporter 3 to the membrane of peptide-functionalized GUVs.
As a control, plain GUVs without CP4K4 were mixed with
CP4E4-functionalized liposomes containing 10 mol% of trans-
porter 3. Aer the addition of the NaCl solution, the lucigenin
emission intensity inside the GUVs did not decrease (Fig. 2, red
circles), proving that transporter 3 was not delivered to the GUV
membrane. Instead, there was a small increase in the uores-
cence intensity. We attribute this increase to the diﬀerence in
osmotic pressure between the inside and the outside of the
GUVs following NaCl addition. This results in a decrease in the
diameter of the GUVs (as detected by bright eld microscopy)
and hence, an increase in lucigenin concentration. We conclude
that omission of the lipopeptide CP4K4 from the membrane of
GUVs inhibits the delivery of transporter 3 to GUVs. Thus,
membrane fusion induced by the lipopeptides 1 and 2 is
required for the targeted delivery of transporter 3 to the
membrane of GUVs.
In a second control experiment, we omitted transporter 3
from the CP4E4 liposomes. Aer membrane fusion, we added
the NaCl solution and monitored the lucigenin emission
intensity. Again the uorescence of GUVs increased (Fig. 2,
green diamonds), presumably due to GUV shrinkage. This
result suggests that the fusion of peptide-decorated liposomes
and GUVs neither makes the lipid membrane permeable to
1770 | Chem. Sci., 2016, 7, 1768–1772 This journal is © The Royal Society of Chemistry 2016
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chloride ions nor induces leakage of the encapsulated lucigenin
uorophore from GUVs. We conclude that coiled-coil driven
membrane fusion is a specic and highly eﬃcient system to
deliver anionophores to GUVs.
To determine whether the lipopeptides 1 and 2 can also be
used to deliver the lipophilic transporter 3 to live cells, we used
cells engineered to express a halide-sensitive uorophore. We
selected for this study Fischer Rat Thyroid (FRT) cells express-
ing the halide-sensitive uorophore yellow uorescent protein
(YFP) variant H148Q/I152L, which is highly sensitive for iodide
vs. chloride (hereaer termed YFP-FRT cells);32,33 FRT cells are
a model system used to investigate epithelial ion transport.34
We demonstrated recently that YFP-FRT cells can be used to
study chloride/iodide exchange by anionophores, bymonitoring
iodide-induced uorescence quenching.19 Herein, we use our
membrane fusion system for the targeted delivery of transporter
3 to the plasma membrane of YFP-FRT cells. Using the same
protocol as that presented in Fig. 1 to deliver 3 to GUVs, the
plasma membrane of YFP-FRT cells was functionalized with
CP4K4 by incubating the cells for 2 hours at 37 C with the CP4K4
lipopeptide 1 in phosphate-buﬀered saline (PBS), followed by
the addition and incubation with CP4E4 liposomes containing
10 mol% anion transporter 3 for 1 h at 37 C. The YFP-FRT cells
were then transferred to a perfusion chamber mounted on the
stage of a uorescence microscope and perfused with PBS.
Aer several minutes the PBS ow was changed to a PBS
solution containing NaI (10 mM) for 5 minutes. This change of
the external buﬀer led to a rapid and robust quenching of cell
uorescence (Fig. S9 in the ESI†). This decrease in cell uores-
cence was almost completely reversed when NaI was washed
from the extracellular solution with fresh PBS, indicating the
eﬃcient and reversible exchange of chloride and iodide by
anionophore 3. Repeating the exposure to NaI aer an interval
of 20 minutes elicited a further rapid quenching of cellular
uorescence followed by a recovery aer washing NaI from the
extracellular solution once more with PBS. We performed two
control experiments by treating the YFP-FRT cells with either
plain POPC liposomes containing transporter 3, the delivery
method used in our previous work,19 or with the targeted
delivery system without 3 (Fig. 3).
The magnitude of the uorescence decay in both control
experiments was signicantly smaller than that elicited by the
use of the membrane fusion lipopeptides 1 and 2 for the
delivery of anionophore 3. The result of the rst control exper-
iment is in agreement with the inability of 3 to be exchanged
between membranes without membrane fusion (Fig. S1 inFig. 2 Averaged normalized lucigenin emission intensity after the
addition of NaCl (t ¼ 40 s) to: CP4K4-functionalized GUVs treated with
CP4E4 liposomes containing the transporter 3 (blue triangles); plain
GUVs treated with CP4E4 liposomes containing the transporter 3 (red
circles); CP4K4-functionalized GUVs treated with CP4E4 liposomes
without transporter 3 (green diamonds). The background photo-
bleaching of CP4K4-decorated GUVs (no NaCl added) is shown as
black squares. The normalized ﬂuorescence traces plotted are the
averages of three independent membrane fusion experiments on
three diﬀerent individual GUVs. Data are means  SEM. For individual
experiments, see Fig. S5–S8, ESI.† The arrow indicates the addition of
NaCl after 40 seconds of time lapse imaging.
Fig. 3 Targeted delivery of the anion transporter 3 to the plasma
membrane of YFP-FRT cells by membrane fusion. (A) Representative
time courses of normalized cell ﬂuorescence and (B) anion transport
activity determined from the initial slope of the ﬂuorescence decay for
the indicated experimental conditions. Dashed lines in (A) indicate the
ﬁt of exponential functions to the ﬁrst twominutes of the ﬂuorescence
decay following NaI (10 mM) addition. Data are means SEM (n¼ 25–
45 cells from 5 independent experiments); **P < 0.01 vs. lipopeptides 1
and 2.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 1768–1772 | 1771
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
7 
Ja
nu
ar
y 
20
16
. D
ow
nl
oa
de
d 
on
 0
6/
09
/2
01
6 
17
:2
2:
40
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
ESI†). The data are also consistent with the control experiments
performed using liposomes and GUVs (Fig. 2). Thus, the highly
lipophilic anion transporter 3 can be successfully delivered to
CP4K4-functionalized YFP-FRT cells via coiled-coil-driven
membrane fusion, where it eﬃciently transports anions across
the plasma membrane of YFP-FRT cells.
Conclusions
In conclusion, we demonstrate that the lipidated coiled-coil
forming peptides 1 and 2 function as a highly specic molecular
recognition system that facilitates membrane fusion. This
synthetic model system can be applied as a fast and eﬃcient tool
in drug delivery studies. We use a supramolecular approach to
solve the deliverability problem of a lipophilic anionophore, with
powerful anion transport activity by leakage-free membrane
fusion between cell-sized GUVs and liposomes. Similar results
were observed using cells engineered to express a halide-sensitive
uorophore. We envisage the topical delivery of the fusogenic
lipopeptides and anionophore to the lungs in which peptide 1
and subsequently liposomes carrying peptide 2 and anionophore
3 are inhaled. This raises the hope that the system can be used to
deliver anionophores to the apical membrane of airway epithelia,
the key target tissue in cystic brosis. There is also potential for
extending the method to deliver other poorly soluble molecules
to biological membranes.
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